Korecyte Bio Ltd. is a UK-based biotechnology company pioneering in vivo CAR-T therapies. Our platform programmes the body to generate tumour-targeting immune cells that overcome solid tumour defences by tackling heterogeneity and immune suppression with unmatched precision, offering a potent therapy capable of treating multiple solid cancers.
Ground-breaking platform technology ‘HypoxiCAR’
Our team has developed HypoxiCAR, a ground-breaking modular platform that programmes a patient’s immune cells to attack cancer with superior precision capable of delivering highly potent payloads that prime the tumour for elimination. Our cells, once generated in a patient, circulate silently until they sense the tumour, then awaken to attack aggressively. By combining all essential elements in a single, integrated therapy, our therapies are designed to overcome the complex defences of solid tumours. Driven by the challenges patients face, we are committed to delivering CAR-T therapies that are safe, effective, and capable of eradicating solid cancers.
More about Korecyte Bio
News & stories about Korecyte Bio
In our News section, you will find our most recent posts, announcements, lists of events we will be attending and other useful information about Korecyte Bio. You can also find our most recent posts on LinkedIn and in our News section.
